Patents Assigned to ZymoGenetics
  • Methods of using biologically active dimerized polypeptide fusions to detect PDGF
    Patent number: 5567584
    Abstract: Methods for producing secreted receptor analogs and biologically active peptide dimers are disclosed. The methods for producing secreted receptor analogs and biologically active peptide dimers utilize a DNA sequence encoding a receptor analog or a peptide requiring dimerization for biological activity joined to a dimerizing protein. The receptor analog includes a ligand-binding domain. Polypeptides comprising essentially the extracellular domain of a human PDGF receptor fused to dimerizing proteins, the portion being capable of binding human PDGF or an isoform thereof, are also disclosed. The polypeptides may be used within methods for determining the presence of and for purifying human PDGF or isoforms thereof.
    Type: Grant
    Filed: January 11, 1994
    Date of Patent: October 22, 1996
    Assignee: Zymogenetics, Inc.
    Inventors: Andrzej Z. Sledziewski, Lillian A. Bell, Wayne R. Kindsvogel
  • Methods for inhibiting hyperproliferation of kerntinocytes
    Patent number: 5552413
    Abstract: Methods and pharmaceutical compositions for the treatment of dermatitis are disclosed. 2,3-diaryl-1-benzopyrans and their pharmaceutically acceptable salts are formulated into medicaments, including oral and topical medicaments, which are administered to a patient suffering from dermatitis. The methods and compositions are particularly useful in the treatment of conditions characterized by hyperproliferation of keratinocytes, such as psoriasis.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: September 3, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Virender M. Labroo, James R. Piggott
  • PAF synthesis modulators
    Patent number: 5550148
    Abstract: Compounds that selectively modulate the remodeling pathway of platelet activating factor (PAF) are described. Related pharmaceutical compositions and methods are also disclosed. These compounds, pharmaceutical compositions and methods are useful for reducing or eliminating inflammation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 27, 1996
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Robert R. West, Jeffrey Van Ness, Annemarie R. Varming
  • A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III
    Patent number: 5545615
    Abstract: Methods for inhibiting fertilization in warm-blooded animals are disclosed. The methods generally comprise administering to the animal an effective amount of a composition comprising a protein that forms a covalent complex with acrosin, and a physiologically acceptable carrier or diluent. Suitable proteins for use in the methods include members of the serpin family of proteins, such as alpha-1-antitrypsin.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: August 13, 1996
    Assignee: ZymoGenetics, Inc.
    Inventor: John M. Maraganore
  • Colony-stimulating factor derivatives
    Patent number: 5545536
    Abstract: Novel proteins possessing substantially the same biological activity as human GM-CSF, as well as proteins having a higher specific activity than native human GM-CSF, are disclosed. The proteins may (a) be unglycosylated; (b) lack N-linked glycosylation but have O-linked glycosylation; or (c) lack one of the two N-linked carbohydrate chains characteristic of native human GM-CSF. The proteins are produced using recombinant DNA techniques in eucaryotic host cells, such as mammalian, yeast, and filamentous fungal host cells. Pharmaceutical compositions including an effective amount of one of the proteins of the invention and a physiologically acceptable carrier or diluent are also disclosed.
    Type: Grant
    Filed: April 27, 1988
    Date of Patent: August 13, 1996
    Assignees: University of Washington, ZymoGenetics, Inc.
    Inventors: Kenneth Kaushansky, Frederick S. Hagen
  • Method for preparing orphan receptor ligands
    Patent number: 5541085
    Abstract: Methods for obtaining cells that produce a ligand for an orphan receptor and methods for preparing polynucleotide molecules that encode ligands for orphan receptors are disclosed. The methods utilize growth factor-dependent parent cells that are transfected with a DNA construct encoding an orphan receptor. The transfected cells are exposed to mutagenizing conditions, and the mutagenized cells are cultured under conditions in which cell survival is dependent upon autocrine growth factor production. Progeny cells are recovered and screened to identify those that produce a ligand for the orphan receptor. Polynucleotide molecules encoding the ligand can be prepared from the identified cells.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: July 30, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Richard D. Holly, Steven K. Burkhead
  • Compositions and methods for stimulating the growth of osteoblasts
    Patent number: 5533836
    Abstract: Methods and compositions for stimulating the growth of osteoblasts are disclosed. A composition comprising platelet derived growth factor and vitamin D is applied to osteoblasts in an amount sufficient to stimulate their growth. The methods may be used to promote the growth of osteoblasts in vitro or to promote the healing of bone defects in vivo.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: July 9, 1996
    Assignee: ZymoGenetics, Inc.
    Inventor: Emma E. Moore
  • Stable DNA constructs
    Patent number: 5527668
    Abstract: Methods are provided for producing protein products in host cells and for selecting transformed cells comprising the step of transforming the host cell with a DNA molecule comprising a gene which complements a deficiency in the host cell. The host cell is a strain having a deficiency in a function necessary for normal cell growth. The gene in the DNA molecule, such as a plasmid, which complements the deficiency serves as a selection marker whereby the growth conditions for selection may comprise a conventional complex medium.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: June 18, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Glenn Kawasaki, Leslie Bell
  • Methods for producing thrombin
    Patent number: 5527692
    Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 18, 1996
    Assignee: Zymogenetics, Inc.
    Inventors: Richard D. Holly, Donald C. Foster
  • Biologically active B-chain homodimers
    Patent number: 5516896
    Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: May 14, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark J. Murray, James D. Kelly
  • Production of activated protein C
    Patent number: 5516650
    Abstract: Methods are disclosed for producing a protein which has substantially the same biological activity as human protein C or human activated protein C. The protein is produced by mammalian host cells transfected with a plasmid capable of integration in mammalian host cell DNA. The plasmid includes a promoter followed downstream by a nucleotide sequence which encodes a protein having substantially the same structure and/or activity as human protein C or human activated protein C the nucleotide sequence being followed downstream by a polyadenylation signal.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: May 14, 1996
    Assignee: Zymogenetics, Inc.
    Inventors: Donald C. Foster, Mark J. Murray, Kathleen L. Berkner
  • Human transglutaminases
    Patent number: 5514579
    Abstract: Human prostatic and placental transglutaminases are identified and cloned. The human transglutaminases herein are useful for, inter alia, therapeutic wound repair, closure of skin grafts, stabilizing food preparations, and markers for identifying agents which act as agonists or antagonists of cellular apoptosis.
    Type: Grant
    Filed: December 30, 1992
    Date of Patent: May 7, 1996
    Assignee: Zymogenetics, Inc.
    Inventors: Patrick J. O'Hara, Francis J. Grant, Paul O. Sheppard
  • Glucagon antagonists
    Patent number: 5510459
    Abstract: Methods for detecting glucagon antagonists through the use of recombinant DNA techniques are provided. Briefly, subsequent to the expression of glucagon analogs within suitable host cells, the analogs are exposed to a glucagon receptor coupled to a response pathway in the presence of native glucagon. A reduction in the stimulation of the response pathway resulting from the binding of the glucagon analog to the glucagon receptor relative to the stimulation of the response pathway by native glucagon alone indicates the presence of a glucagon antagonist. Glucagon antagonists identified and isolated through the methods are also provided.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: April 23, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Robert A. Smith, James R. Piggott
  • Glucagon antagonists and methods relating thereto
    Patent number: 5508304
    Abstract: Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: April 16, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Robert R. West, Virender Labroo, James R. Piggott, Robert A. Smith, Patricia A. McKernan
  • Hybrid plasminogen activator
    Patent number: 5504001
    Abstract: Hybrid proteins comprising a cross-linking domain derived from a protein that acts as an acyl-donor substrate for factor XIIIa, a fibrin-binding domain, and a serine protease domain are disclosed. Host cells transfected or transformed with an expression vector comprising a transcriptional promoter operably linked to a DNA sequence encoding such hybrid proteins are also disclosed, as well as methods for producing the proteins. The proteins may be utilized in combination with a suitable carrier or diluent as pharmaceutical compositions.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: April 2, 1996
    Assignee: ZymoGenetics, Inc.
    Inventor: Donald C. Foster
  • Methods for producing thrombin
    Patent number: 5502034
    Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 26, 1996
    Assignee: Zymogenetics, Inc.
    Inventors: Richard D. Holly, Donald C. Foster
  • Biologically active mosaic proteins
    Patent number: 5498600
    Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, the proteins being chemotactic or mitogenic for fibroblasts. Alternatively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: March 12, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark J. Murray, James D. Kelly
  • Tissue plasminogen activator analogs having modified growth factor domains
    Patent number: 5486471
    Abstract: Tissue plasminogen activator analogs containing the growth factor domain of native t-PA, the domain having at least one cysteine residue replaced with another amino acid. The t-PA analogs may further contain a variety of substitutions and/or modifications. Pharmaceutical compositions containing one or more of the t-PA analogs along With a physiologically acceptable carrier or diluent are also disclosed.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: January 23, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Eileen R. Mulvihill, Shinji Yoshitake, Yasunori Ikeda, Suguru Suzuki, Akira Hashimoto, Teruaki Yuzuriha, Bjorn A. Nexo
  • 3,4-diarylchromans for inhibiting calmodulin activity
    Patent number: 5480903
    Abstract: A method for inhibiting is disclosed comprising administering, 3,4-diarylchromans and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: April 17, 1994
    Date of Patent: January 2, 1996
    Assignee: ZymoGenetics, Inc.
    Inventor: James R. Piggott
  • Methods for producing thrombin
    Patent number: 5476777
    Abstract: Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.
    Type: Grant
    Filed: December 30, 1992
    Date of Patent: December 19, 1995
    Assignee: Zymogenetics, Inc.
    Inventors: Richard D. Holly, Donald C. Foster